A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Shares of Leap Therapeutics, Inc. nosedived more than 70% to an all-time low on Tuesday, making them the top loser across U.S. exchanges. The sharp drop — Leap’s worst intraday fall ever — came after ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

and bevacizumab (Avastin) alone, reported Richard S. Finn, MD, of the University of California Los Angeles, and colleagues. In addition, the median progression-free survival (PFS) was 12.3 months ...

Compounded bevacizumab formulations are sometimes used to treat wet AMD but, because the reference product (Roche's Avastin) is only indicated for cancer conditions, they can only be used off ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

However, Roche faced a CHF 1bn sales decline from the loss of exclusivity on older products, including cancer therapies ...